Journal Article

Access denied: a review and critique of the Patented Medicines (Notice of Compliance) Regulations

Mohamed R. Hashim

in Journal of Intellectual Property Law & Practice

Volume 8, issue 1, pages 23-32
Published in print January 2013 | ISSN: 1747-1532
Published online January 2013 | e-ISSN: 1747-1540 | DOI: http://dx.doi.org/10.1093/jiplp/jps186
Access denied: a review and critique of the Patented Medicines (Notice of Compliance) Regulations

More Like This

Show all results sharing these subjects:

  • Arbitration
  • Intellectual Property Law

GO

Show Summary Details

Preview

Mohamed R. Hashim, B.A., LL.B., LL.M, Called to the Ontario Bar 2010.

In Canada, proceedings brought under the Patented Medicines (Notice of Compliance) Regulations are among the most contentious. At stake is a pharmaceutical company's ability to enter a drug onto the market.

Applications under the PMNOC regime involve an innovator, or brand, company pitted against a generic drug-making company, wherein the brand company seeks to prohibit the generic from releasing a generic drug until the expiry of listed patents.

In practice, the Regulations create many obstacles for the release of generic drugs. This paper reviews the provisions and critically evaluates the process of obtaining approval to release a generic drug. It is submitted, the PMNOC Regulations do not provide ideal conditions for efficient patent litigation. The provisions create undesirable litigation practices and ultimately result in a loss for the Canadian people.

Journal Article.  7535 words. 

Subjects: Arbitration ; Intellectual Property Law

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.